
    
      This is a follow-up study to a multi-centre, randomised, double-blind, placebo controlled,
      parallel group clinical study (TG002) which evaluated the efficacy, safety and tolerability
      of three doses of ToleroMune Grass versus placebo in grass allergic subjects. Subjects who
      completed TG002 in calendar year 2012 will undergo a further single exposure to grass
      allergens in an EEU.
    
  